Biotechnology News

All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE...

Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage...

Heidelberg, Germany, August 25, 2026 – Revier Therapeutics (“Revier” or “the Company”), today announced the closing of a EUR 6 million seed financing and the launch of its operations. The Company has...

Heidelberg, Deutschland, 25. August 2026 – Revier Therapeutics („Revier“ oder „das Unternehmen“) gab heute den erfolgreichen Abschluss einer Seed-Finanzierungsrunde in Höhe von 6 Millionen € sowie die...

Company announcement no. 32 - 2625 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...

Longeveron announced that it will undertake a 1-for-10 reverse split of the Company’s Class A common stock and Class B common stock.

MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new...

Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has...

Mechelen, België; 24 augustus, 2026, 22.01 CET; gereglementeerde informatie – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) kondigt vandaag aan dat de Amerikaanse Food and Drug...